WallStreetZenWallStreetZen

NASDAQ: ATXS
Astria Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ATXS

Based on 5 analysts offering 12 month price targets for Astria Therapeutics Inc

Min Forecast
$16.00+145.02%
Avg Forecast
$32.80+402.3%
Max Forecast
$47.00+619.75%

Should I buy or sell ATXS stock?

Based on 5 analysts offering ratings for Astria Therapeutics Inc.

Strong Buy
Strong Buy
2 analysts 40%
Buy
3 analysts 60%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although ATXS's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates ATXS as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their ATXS stock forecasts and price targets.

ATXS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-08-13
lockedlocked$00.00+00.00%2025-08-13
lockedlocked$00.00+00.00%2025-05-14
lockedlocked$00.00+00.00%2025-04-29
lockedlocked$00.00+00.00%2025-03-12

1 of 1

Forecast return on equity

Is ATXS forecast to generate an efficient return?

Company
-32.01%
Industry
121.84%
Market
-49.65%
ATXS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ATXS forecast to generate an efficient return on assets?

Company
-29.58%
Industry
45.6%
ATXS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ATXS earnings per share forecast

What is ATXS's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$2.09
Avg 2 year Forecast
-$2.25
Avg 3 year Forecast
-$2.27

ATXS revenue forecast

What is ATXS's revenue in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$17.0M
Avg 2 year Forecast
$6.5M
Avg 3 year Forecast
$9.5M

ATXS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ATXS$6.53$32.80+402.30%Strong Buy
ABSI$2.47$7.98+223.00%Strong Buy
ADCT$3.25$7.75+138.46%Strong Buy
NKTR$29.34$81.25+176.93%Strong Buy
RCKT$3.35$15.19+353.49%Buy
View Top Biotech Stocks

Astria Therapeutics Stock Forecast FAQ

Is Astria Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: ATXS) stock is to Strong Buy ATXS stock.

Out of 5 analysts, 2 (40%) are recommending ATXS as a Strong Buy, 3 (60%) are recommending ATXS as a Buy, 0 (0%) are recommending ATXS as a Hold, 0 (0%) are recommending ATXS as a Sell, and 0 (0%) are recommending ATXS as a Strong Sell.

If you're new to stock investing, here's how to buy Astria Therapeutics stock.

What is ATXS's earnings growth forecast for 2025-2027?

(NASDAQ: ATXS) Astria Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.19%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 14.9%.

Astria Therapeutics's earnings in 2025 is -$116,921,000.On average, 6 Wall Street analysts forecast ATXS's earnings for 2025 to be -$117,666,754, with the lowest ATXS earnings forecast at -$142,780,282, and the highest ATXS earnings forecast at -$102,147,158. On average, 5 Wall Street analysts forecast ATXS's earnings for 2026 to be -$126,752,772, with the lowest ATXS earnings forecast at -$142,215,933, and the highest ATXS earnings forecast at -$110,048,043.

In 2027, ATXS is forecast to generate -$128,107,209 in earnings, with the lowest earnings forecast at -$141,651,584 and the highest earnings forecast at -$113,998,486.

What is ATXS's revenue growth forecast for 2025-2027?

(NASDAQ: ATXS) Astria Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 82.71%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.57%.

Astria Therapeutics's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast ATXS's revenue for 2025 to be $959,393,198, with the lowest ATXS revenue forecast at $902,958,304, and the highest ATXS revenue forecast at $1,015,828,092. On average, 2 Wall Street analysts forecast ATXS's revenue for 2026 to be $366,826,811, with the lowest ATXS revenue forecast at $282,174,470, and the highest ATXS revenue forecast at $451,479,152.

In 2027, ATXS is forecast to generate $533,309,748 in revenue, with the lowest revenue forecast at $225,739,576 and the highest revenue forecast at $840,879,921.

What is ATXS's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: ATXS) forecast ROA is -29.58%, which is lower than the forecast US Biotechnology industry average of 45.6%.

What is ATXS's Price Target?

According to 5 Wall Street analysts that have issued a 1 year ATXS price target, the average ATXS price target is $32.80, with the highest ATXS stock price forecast at $47.00 and the lowest ATXS stock price forecast at $16.00.

On average, Wall Street analysts predict that Astria Therapeutics's share price could reach $32.80 by Aug 13, 2026. The average Astria Therapeutics stock price prediction forecasts a potential upside of 402.3% from the current ATXS share price of $6.53.

What is ATXS's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: ATXS) Astria Therapeutics's current Earnings Per Share (EPS) is -$2.01. On average, analysts forecast that ATXS's EPS will be -$2.09 for 2025, with the lowest EPS forecast at -$2.53, and the highest EPS forecast at -$1.81. On average, analysts forecast that ATXS's EPS will be -$2.25 for 2026, with the lowest EPS forecast at -$2.52, and the highest EPS forecast at -$1.95. In 2027, ATXS's EPS is forecast to hit -$2.27 (min: -$2.51, max: -$2.02).

What is ATXS's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: ATXS) forecast ROE is -32.01%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.